Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.260
+0.240 (11.88%)
At close: Jun 26, 2026, 4:00 PM EDT
2.286
+0.026 (1.14%)
After-hours: Jun 26, 2026, 7:57 PM EDT
Spero Therapeutics Employees
Spero Therapeutics had 25 employees as of December 31, 2025. The number of employees decreased by 7 or -21.88% compared to the previous year.
Employees
25
Change (1Y)
-7
Growth (1Y)
-21.88%
Revenue / Employee
$2,447,440
Profits / Employee
$609,400
Market Cap
130.86M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Fractyl Health | 100 |
| enGene Therapeutics | 82 |
| Agenus | 81 |
| PepGen | 56 |
| Oncolytics Biotech | 29 |
| Genelux | 26 |
| Coya Therapeutics | 8 |
| Aldeyra Therapeutics | 7 |
SPRO News
- 4 days ago - Spero Therapeutics Transcript: AGM 2026 - Transcripts
- 10 days ago - Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) - Business Wire
- 10 days ago - GSK, Spero Therapeutics announce FDA approval of Utebzi - TheFly
- 6 weeks ago - Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Spero Therapeutics Earnings release: Q1 2026 - Filings
- 6 weeks ago - Spero Therapeutics Quarterly report: Q1 2026 - Filings
- 7 weeks ago - Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 - GlobeNewsWire
- 2 months ago - Spero Therapeutics Proxy statement: Proxy filing - Filings